CAR T-Cell Therapy cost in India
CAR T-cell therapy cost in India can range from $45000 to $85000, which is equivalent to approximately 38,50,000 to 75,00,000 Indian rupees. CAR T-cell therapy is an advanced treatment where a patient's T cells, which are crucial to the immune system, are altered in a lab to specifically target and destroy cancer cells.
The process begins with extracting T cells from the patient's blood, which are then genetically engineered to display chimeric antigen receptors (CARs) on their surface. After modification, these CAR T cells are multiplied in the lab and reintroduced into the patient's body via infusion. This therapy is uniquely personalized for each patient and has shown great success in treating difficult cancers like leukemia and lymphoma. Ongoing research explores its potential to treat other cancer types.
Estimated Cost of CAR T-Cell Therapy
CAR T-cell therapy offers the advantage of a shorter treatment duration compared to traditional cancer therapies. It provides long-term remission and an improved quality of life for patients, often surpassing conventional approaches. Unlike stem cell transplants, which involve intensive chemotherapy, CAR T-cell therapy generally results in a quicker recovery for most patients.
Additionally, CAR T-cells differ from Tumor Infiltrating Lymphocytes (TILs) and T Cell Receptors (TCRs) as they do not rely on Major Histocompatibility Complex (MHC) expression for antigen recognition. This unique ability allows CAR T-cells to recognize specific antigens independently of antigen processing by the target cells and MHC restrictions, leading to more effective tumor cell destruction.
We Handle the Planning
You Focus on Recovery
From Medical Visa assistance to airport pick-up and local stay, HOSPIDIO manages your entire medical trip.
Tell Us About Your Need
Free case review. Confidential. No obligation.CAR T-Cell Therapy Cost in India vs Other Countries
India offers CAR T-cell therapy at 85%-90% lower cost than the United States and United Kingdom. Below is a comparison of approximate treatment costs across major medical tourism destinations:
| Country | CAR T-Cell Therapy Cost (USD) | Savings vs India |
| India | $45,000 - $85,000 | - |
| USA | $400,000 - $500,000 | You save $355,000 - $415,000 |
| UK | $350,000 - $450,000 | You save $305,000 - $365,000 |
| Thailand | $120,000 - $180,000 | You save $75,000 - $95,000 |
| Turkey | $80,000 - $130,000 | You save $35,000 - $45,000 |
Costs above are approximate and vary by hospital, drug brand, patient condition, and currency exchange rates. Contact HOSPIDIO for a personalised cost estimate based on your specific reports.
CAR T-Cell Therapy Cost by City in India
The cost of CAR T-cell therapy also varies by city depending on the hospital, available CAR-T products, and local infrastructure. Here is an indicative range by major treatment cities:
| City | Approx. Cost Range (USD) | Key Hospitals |
| Mumbai | $50,000 – $85,000 | Kokilaben Dhirubhai Ambani, Jaslok, Reliance HN |
| Delhi / Gurgaon | $45,000 – $80,000 | BLK-Max, Medanta, Artemis, Max Saket |
| Chennai | $48,000 – $80,000 | Gleneagles Global Health City, Apollo Proton Cancer Centre |
| Hyderabad | $45,000 – $75,000 | AIG Hospitals, KIMS |
Mumbai and Delhi are the primary hubs for CAR T-cell therapy in India, offering both imported therapies (Kymriah, Yescarta) and India's own NexCAR19. Most hospitals require a minimum 25–30 day inpatient stay.
Who is a candidate for CAR T-cell therapy in India?
In India, candidates for CAR T-cell therapy are typically patients with certain types of cancers that have not responded to conventional treatments, such as chemotherapy or radiation. The most common cancers for which CAR T-cell therapy is currently approved include:
Relapsed or Refractory Blood Cancers
Patients with certain types of blood cancers, such as B-cell acute lymphoblastic leukemia (ALL) in children and young adults, and certain types of non-Hodgkin lymphoma (NHL) like diffuse large B-cell lymphoma (DLBCL), who have not responded to standard treatments, may be considered.
Eligibility Criteria
- Disease Status: The patient should have relapsed or refractory disease after at least two prior lines of therapy.
- Health Condition: The patient should be in a reasonably good health condition to withstand the treatment, as CAR T-cell therapy can cause side effects in certain patients, including cytokine release syndrome (CRS) and neurological toxicities.
- Medical Evaluation: A thorough medical evaluation is conducted to assess whether the patient is a suitable candidate, including considering factors like the patient's overall health, comorbidities, and prior treatment history.
- Availability: As CAR T-cell therapy is relatively new in India, it is mostly available through specialized cancer centers. Patients should consult with oncologists at institutions offering CAR T-cell therapy to determine if they are eligible.
- 4.7
- 9k Reviews
- (Google)
- 1k+ Beds
- 40+ Departments
- 300+ Doctors
- 55k+ Intl. Patients
- 4.1
- 5k Reviews
- (Google)
- 750+ Beds
- 40+ Departments
- 400+ Doctors
- 35k+ Intl. Patients
- 4.8
- 11k Reviews
- (Google)
- 345+ Beds
- 50+ Departments
- 250+ Doctors
- 60k+ Intl. Patients
- 4.6
- 15k Reviews
- (Google)
- 370+ Beds
- 35+ Departments
- 259+ Doctors
- 33k+ Intl. Patients
- 4.6
- 18k Reviews
- (Google)
- 650+ Beds
- 60+ Departments
- 300+ Doctors
- 90k+ Intl. Patients
- 4.8
- 11k Reviews
- (Google)
- 350+ Beds
- 50+ Departments
- 300+ Doctors
- 65k+ Intl. Patients
- 4.5
- 5k Reviews
- (Google)
- 350+ Beds
- 55+ Departments
- 200+ Doctors
- 50k+ Intl. Patients
- 4.2
- 8k Reviews
- (Google)
- 539+ Beds
- 38+ Departments
- 541+ Doctors
- 80k+ Intl. Patients
- 4.6
- 12k Reviews
- (Google)
- 330+ Beds
- 30+ Departments
- 250+ Doctors
- 72k+ Intl. Patients
- 4.2
- 9k Reviews
- (Google)
- 1k+ Beds
- 30+ Departments
- 900+ Doctors
- 125k+ Intl. Patients
- 3.8
- 4k Reviews
- (Google)
- 750+ Beds
- 35+ Departments
- 410+ Doctors
- 25k+ Intl. Patients
- 4.9
- 5k Reviews
- (Google)
- 150+ Beds
- 10+ Departments
- 30+ Doctors
- 2k+ Intl. Patients
Types of CAR T-Cell Therapy Treatment Cost
Here is an overview of the common types of CAR-T Cell therapy surgeries along with their approximate cost range in USD:
Type of FDA Approved CAR T-Cell Therapy in India | Diagnosis | Cost Range in USD |
| Kymriah | B-Cell Acute Lymphoblastic Leukemia (ALL)B-Cell Non-Hodgkin's Lymphoma (NHL) | 65000 - 85000 |
| Yescarta | B-Cell Non-Hodgkin's Lymphoma (NHL)Follicular Lymphoma | 65000 - 85000 |
| Tecartus | Mantle Cell Lymphoma (MCL)B-Cell Acute Lymphoblastic Leukemia (ALL) | 65000 - 85000 |
| Breyanzi | B-Cell Non-Hodgkin's Lymphoma (NHL) | 65000 - 85000 |
| Abecma | Multiple Myeloma | 45000 - 65000 |
| Carvykti | Multiple Myeloma | 45000 - 65000 |
NexCAR19 - India's Own CAR T-Cell Therapy at a Fraction of the Cost
In October 2024, India's drug regulator (DCGI) approved NexCAR19, the country's first indigenously developed CAR T-cell therapy. Created by ImmunoACT, a startup incubated at IIT Bombay, NexCAR19 targets CD19 and is indicated for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL).
What makes NexCAR19 significant for international patients is its price. While imported CAR-T therapies like Kymriah cost $65,000-$85,000 in India (and up to $475,000 in the United States), NexCAR19 is available at approximately ₹40 lakh to ₹50 lakh (around $47,000-$65,000), making it the most affordable approved CAR T-cell therapy in the world.
NexCAR19 uses a humanised anti-CD19 CAR construct, which reduces the risk of cytokine release syndrome (CRS) compared to fully murine constructs used in older therapies.
CAR T-Cell Therapy Cost in India Inclusions
CAR T-cell therapy infusions
Routine medicines and consumables required during treatment
CAR T-Cell Therapy Cost in India Exclusions
Pre-treatment examination and tests related to staging of cancer
Meals and flights
Hospital and hotel stay
Post-treatment follow-ups and management
Treatment for any other underlying medical conditions
Any complex investigations or medicines
Anything not covered in the package
Other Factors Affecting CAR T-Cell Therapy Cost in India
Age of the patient and symptoms
Type of blood cancer (how much it has spread)
Stage and grade of cancer
Pre-existing medical history
Recommended treatment and duration
Number and type of treatment modalities advised
Diagnostic Tests Required Before CAR T-Cell Therapy Treatment
Types of Tests For CAR T-Cell Therapy Treatment in India | Cost Range in USD |
Blood tests These include the basic blood investigations for the patient to check organ functioning, infection status and coagulation profile. | 50 to 100 |
Radiological Assessment MRI, CT or any other tests to check for location of the disease. This may also include an endoscopic ultrasound (EUS). | 150 to 250 |
Histopathology Examination This includes tests such as biopsy for examination under a microscope. | 150 to 250 |
Full Body PET Scan This includes a full body PET FDG scan to check for an metastasis and establish the stage of the cancer. | 400 to 600 |
| Assessment for Cytokine Release Syndrome (CRS)Although not a diagnostic test, understanding the risk of CRS and preparing for its management is crucial. Cardiac and pulmonary assessment is also planned alongside. | 100 to 150 |
Why is India preferred as one of the best countries for CAR T-Cell Therapy Treatment?
India is becoming a preferred destination for CAR T-cell therapy due to several compelling reasons. The treatment is often more cost-effective in India compared to Western countries, making it accessible to a broader range of patients. Additionally, India boasts advanced medical facilities equipped with state-of-the-art technology and skilled professionals who specialize in CAR T-cell therapy.
Indian oncologists have extensive experience and expertise gained through global collaborations and research, ensuring high-quality care. Comprehensive patient care, including thorough pre-treatment evaluations, personalized treatment plans, and robust post-treatment support, is a hallmark of Indian hospitals. The country also serves as a hub for clinical trials, providing access to the latest therapies. Furthermore, India offers multilingual services and patient-centric care, which are advantageous for international patients. Favorable regulations and streamlined processes for medical visas and treatment approvals further facilitate access to this advanced treatment. These factors collectively enhance India's reputation as a leading destination for CAR T-cell therapy.
Why International Patients Trust HOSPIDIO as Their Travel Partner
- Multilingual Support: Language shouldn't be a barrier; we provide expert interpreters.
- Travel & Accommodation: We book stay options near the hospital for you and your attendant.
- Airport-to-Hospital Transfers: Private pick-up and drop-off included.
- Global Continuity: Coordination with your local doctor if required after you return home.
FAQs
CAR T-Cell Therapy is an advanced cancer treatment where a patient’s own T-cells (a type of immune cell) are collected, modified in a lab to recognize cancer cells, and then given back to the patient to attack and kill the cancer.
It is mainly used for certain blood cancers such as:
- Leukemia (Acute Lymphoblastic Leukemia – ALL)
- Lymphoma (Diffuse Large B-cell Lymphoma – DLBCL and others)
- Multiple Myeloma
Yes, CAR T-Cell Therapy is now available in select advanced cancer hospitals in India. The treatment is offered under specialized cancer programs with highly trained experts.
The treatment usually involves these steps:
- Collection – Your T-cells are taken from your blood.
- Modification – The cells are engineered in a lab to target cancer.
- Infusion – Modified cells are infused back into your body.
- Monitoring – You stay in the hospital for close observation.
Success depends on the type of cancer and the patient’s condition. Many patients with resistant blood cancers have achieved long-term remission after CAR T-Cell Therapy. Your oncologist will guide you on expected outcomes.
Yes, once your medical reports are reviewed, we provide a confirmed treatment date typically within one week.
Yes, our surgeons use the same FDA-approved technology and protocols, ensuring world-class outcomes with a 70–90% success rate.
Average cost for CAR T-Cell Therapy in India is $45000 to $85000 USD.
Most e-Medical visas are issued within 48 to 72 hours; we provide the required hospital visa invitation letter instantly to prevent any delays.
Yes, we assist in securing Medical Attendant Visas for up to two companions simultaneously so your support system arrives with you.
Our team handles all local visa extension paperwork at the hospital, ensuring your stay is legally extended until you are medically cleared to fly.
Kymriah (tisagenlecleucel), manufactured by Novartis, costs approximately $65,000-$85,000 in India. This is 80%-85% cheaper than in the United States, where Kymriah is priced at around $475,000. In India, Kymriah is approved for B-cell Acute Lymphoblastic Leukemia (ALL) in patients up to 25 years of age and for relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) in adults. India also now offers NexCAR19, an indigenous alternative for the same indications, at approximately $47,000-$60,000.